American and British talents joined towards science; eight English and American centers have genetically mapped mutations in prostate cancer. Apparently, the latest research may open a new way of treating this type of cancer.
Prostate cancer is the most common among men, with a worldwide prevalence of approximately 900.000 cases.
The study was published in the popular journal Cell, and indicated that 89% of affected individuals could be treated clinically.
The latest developments have been described as “the Rosetta stone of prostate cancer,” as it will allow to decode the complexity of the disease and translate them into a personalized treatment.
Achievements
One of the most encouraging aspects of the discovery is that many of the key mutations that have been identified can be treated by existing anticancer drugs, which shows a new era of personalized treatment disease.
The last study took biopsy samples of lymph nodes, bones, liver and other tissues of 150 men who had undergone surgery to remove their prostate tumors and had hormone treatments to fight cancer. These are cases of castration-resistant prostate cancer, where those affected have a life expectancy of about 19 months.
Drugs, currently being used as inhibitors of poly (ADP-ribose) polymerase (PARP), which were used to fight ovarian cancer or breast, are now tested for prostate cancer treatment.
The work of medical talent from the United States and Britain, represents a great technical achievement, giving hope for solutions and new ways to study health issues that now claim the lives of millions of people around the world.
Thanks to the O1 visa
and J1 visa any health care professional or research scientist can develop professionally in the United States, for more information click here
Talents Involved:
Some of those involved in the study are British Professor Johann de Bono of the Institute for Cancer Research. Bono was born and raised in Malta, and then moved to England where he graduated at the University of Glasgow in 1989. He was a member of the Royal College of Physicians in 1992 and later gained experience in oncology in Seattle in the United States (1996-2000).
US Dr. Eliezer Van Allen; his studies at David Geffen School of Medicine at UCLA and Stanford University opened for him a path of success and numerous awards. He currently works at the Dana Farber Cancer Institute.
Kat Arney : she completed her PhD at the University of Cambridge. Kat writes scientific articles for the website “Naked Scientists” and helps to present different cases and scientists in a radio program in the UK. She is currently manager of information at Cancer Research UK
Iain Frame : he worked for the Diabetes Centre in the UK, where he held the position of Director of Research for five years. Ian previously worked in research at the Wellcome Trust Centre. He is currently Director of the Prostate Cancer Research UK
Philip Kantoff: he graduated from the Medical School of Brown University for 1979. After completing his internship and residency in internal medicine at the Hospital of the University of New York and at Bellevue Hospital, he spent four years at the National Institutes of Health conducting research in gene therapy.
Currently, he is the leader of the Cancer Program at Dana-Farber, Director of Cancer Research Specializing prostate Excellence (SPORE) and Professor of medicine at Harvard.